araag2/HINT huggingface dataset:
Clinical trial NCT00316914 (phase 3, status: completed)
Conditions: colorectal cancer, neurotoxicity
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, G92.00, G92.01, G92.02, G92.03, G92.04, G92.05
Drugs: calcium gluconate, magnesium sulfate
SMILES: [Ca], [MgH2]
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the colon or rectum

               -  Stage II disease

               -  Stage III disease

               -  Stage IV disease (completely resected with no evidence of residual tumor)

          -  Must have undergone curative resection for stage II or III disease

          -  Scheduled to receive 6 months of adjuvant treatment with either of the following
             FOLFOX chemotherapy regimens:

               -  FOLFOX4, comprising leucovorin calcium, fluorouracil, and oxaliplatin (2-week
                  course)

               -  Modified FOLFOX6, comprising high-dose leucovorin calcium, high-dose
                  fluorouracil, and oxaliplatin (2-week course)

        PATIENT CHARACTERISTICS:

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL

          -  WBC ≥ 3,000/mm^3

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  Calcium normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No pre-existing peripheral neuropathy of any grade

          -  No hypercalcemia

          -  No concurrent heart block or a history of heart block

          -  No other medical condition that, in the opinion of the treating physician, would make
             this protocol unreasonably hazardous for the patient

          -  No family history of a genetic/familial neuropathy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior treatment with neurotoxic chemotherapy such as oxaliplatin, cisplatin,
             taxanes, or vinca alkaloids

          -  Concurrent use of bevacizumab or cetuximab in combination with FOLFOX as part of a
             clinical trial or clinical practice are allowed

          -  No concurrent digitalis medication

          -  No concurrent digoxin

          -  No concurrent treatment with anticonvulsants such as carbamazepine, phenytoin, or
             valproic acid

          -  No other concurrent neurotropic agents such as gabapentin
Clinical trial NCT00267943 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan 80 mg + hydrochlorothiazide 25 mg
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Essential hypertension.

          -  Currently taking between one and three antihypertensive medications at a stable dose
             for at least four weeks before Visit 1 of preceding trial 502.480.

          -  Blood pressure not adequately controlled on existing treatment before entry to
             preceding trial 502.480 (inadequate control defined as seated DBP >= 95 mmHg on one
             current antihypertensive medication or DBP >= 90 mmHg on two or more current
             antihypertensive medications).

          -  Failure to respond to six weeks run-in treatment with T80/H12.5 in preceding trial
             502.480. (Failure to respond defined as seated DBP >= 90 mmHg.)

          -  Willing and able to provide written informed consent.

        Exclusion criteria:

          -  Women of child-bearing potential NOT practising acceptable means of birth control,
             positive serum pregnancy test, breastfeeding.

          -  Known or suspected secondary hypertension.

          -  Clinically significant change in ECG reported as adverse event in preceding trial
             502.480.

          -  Any medical condition developing in preceding trial 502.480 that could be worsened by
             telmisartan/HCTZ (80/25).

          -  Discontinuation from preceding 502.480 trial for adverse event or any other reason.

          -  Mean SBP >= 200 mmHg.

          -  Severe hepatic or renal impairment.

          -  Bilateral renal artery stenosis (or in a solitary kidney), post-renal transplant or
             only one functioning kidney.

          -  Clinically relevant hypokalaemia or hyperkalaemia.

          -  Uncorrected volume or sodium depletion, primary aldosteronism.

          -  Hereditary fructose intolerance.

          -  Previous symptoms of angioedema after ACE inhibitors or angiotensin-II receptor
             antagonists.

          -  Drug or alcohol dependency within the six months prior to entry to 502.480. concurrent
             participation in another clinical trial or any investigational therapy.

          -  Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the
             aortic or mitral valve.

          -  Allergic hypersensitivity to any component of the formulations under investigation.

          -  Concomitant therapy with lithium, cholestyramine or colestipol resins.

          -  Non-compliance with study medication (less than 80% or more than 120%) during the
             preceding 502.480 trial.

          -  Any other clinical condition which, in the opinion of the investigator, would not
             allow safe administration of telmisartan or hydrochlorothiazide.
Clinical trial NCT00088530 (phase 3, status: completed)
Conditions: lymphoma, non-hodgkin
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, vinorelbine, oxalplatin, ifosfasmide, etoposide, mitoxatrone, gemcitabine or rituximab
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed aggressive [de novo or transformed] NHL according to REAL/WHO
             classification.

          -  At least one objectively measurable lesion as demonstrated by CT, spiral CT, or MRI
             and plain radiograph of the chest (chest x-ray, for chest lesions only) that can be
             followed for response as target lesion.

          -  Relapse after 2 or more prior regimens of chemotherapy

          -  ECOG performance status of 0, 1, or 2

          -  Adequate hematologic, renal and hepatic function

          -  LVEF ≥50% determined by MUGA scan

        Exclusion Criteria:

          -  Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450
             mg/m²

          -  Prior allogenic stem cell transplant

          -  Histological diagnosis of Burkitt lymphoma, lymphoblastic lymphoma or Mantle cell
             lymphoma

          -  Active CNS lymphoma or HIV-related lymphoma.

          -  Any chemotherapy, radiotherapy, or other anticancer treatment (including
             corticosteroid, 10 or more mg/day of prednisone or equivalent) within the 2 weeks
             before randomization

          -  Pregnant women or nursing mothers
Clinical trial NCT00274014 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        -  Diagnosis of COPD according to the European Respiratory Society (ERS) (R95-3225) and
             matching the following criteria:

               -  Stable moderate to severe airway obstruction

               -  Baseline 30 % < FEV1 < 65 % of European Community of Coal and Steel (ECCS)
                  predicted values (R94-1408).

               -  Baseline FEV1/SVC< 70 %.

          -  Smoking history > 10 pack-years (p.y.). A p.y. was defined as the equivalent of
             smoking

          -  One pack of cigarettes per day for one year.

          -  History of exacerbation in the past year.
Clinical trial NCT00059839 (phase 3, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Newly diagnosed advanced anaplastic large cell lymphoma

               -  Cluster of differentiation antigen 30 (CD30+)

               -  Murphy stage III or IV

          -  No B-cell large cell lymphoma

          -  No disease limited to the skin (regardless of how wide-spread)

        PATIENT CHARACTERISTICS:

        Age

          -  Under 21

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) less than 2.5 times ULN
             (unless due to lymphoma)

        Renal

          -  Not specified

        Cardiovascular

          -  Shortening fraction (SF) at least 27% by echocardiogram OR

          -  Ejection fraction (EF) at least 50% by radionuclide angiogram

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Prior steroids for management of a mediastinal mass allowed

        Radiotherapy

          -  Prior limited-dose radiotherapy for a mediastinal mass allowed

        Surgery

          -  Not specified
Clinical trial NCT00273052 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: carvedilol phosphate modified release formulation, metoprolol succinate
SMILES: COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Documented history of hypertension

          -  Triglycerides of 120-400 mg/mL

          -  LDLc levels not requiring lipid lowering medication.

        Exclusion Criteria:

          -  Has known contraindication to alpha- or beta-blocker therapy.

          -  Has taken any non-ocular beta-blockers within three months before screening.

          -  Has Type I or II diabetes.

          -  Taking lipid lowering medications.
Clinical trial NCT01212770 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: apremilast 20mg, apremilast 30mg, placebo
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females, aged ≥ 18 years at time of consent.

          -  Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.

          -  Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at
             time of screening.

          -  Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)

          -  May not have axial involvement alone

          -  Concurrent Tx allowed with methotrexate, leflunomide, or sulfasalazine

          -  Have ≥ 3 swollen AND ≥ 3 tender joints.

          -  Males & Females must use contraception

          -  Stable dose of NSAIDs, narcotics and low dose oral corticosteroids allowed.

          -  Have at least one ≥2 cm psoriasis lesion

        Exclusion Criteria:

          -  Pregnant or breast feeding.

          -  History of allergy to any component of the investigational product Hepatitis B surface
             antigen and/or Hepatitis C antibody positive at screening.

          -  Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF)
             blocker
Clinical trial NCT00356109 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: human insulin inhalation powder, injectable insulin, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes for at least 24 months

          -  Have an HbA1c less than or equal to 11%

          -  Patients who are on an insulin regimen involving 2 or 3 preprandial injections per day
             for at least 2 months

          -  Non-smoker

        Exclusion Criteria:

          -  Require a daily total insulin dosage greater than 150 U at screening

          -  Patients who have a current or past history of asthma, chronic obstructive pulmonary
             disease, other clinically relevant pulmonary disease

          -  Systemic glucocorticoid therapy

          -  Clinical signs or symptoms of liver disease, acute or chronic hepatitis

          -  History of lung transplantation and/or lung cancer

          -  Diagnosed with pneumonia in the 3 months prior to screening

          -  History of renal transplantation

          -  Active or untreated malignancy
Clinical trial NCT01763905 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: placebo to evolocumab, ezetimibe, placebo to ezetimibe
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  Not on a statin or on a low dose statin with stable dose for at least 4 weeks

          -  History of intolerance to at least 2 statins

          -  Subject not at LDL-C goal

          -  Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks.

          -  Fasting triglycerides ≤ 400 mg/dL

        Exclusion Criteria:

          -  New York Heart Association (NYHA) III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes, poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
Clinical trial NCT00723528 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo (cp), ustekinumab 45 mg (cp), ustekinumab 90 mg (cp), placebo a (after cp), placebo b (after cp), ustekinumab 45 mg (after cp), ustekinumab 90 mg (after cp)
SMILES: C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants diagnosed with psoriasis (psoriasis vulgaris and psoriatic arthritis) at
             least 6 months before registration

          -  Participants with plaque type psoriasis covering at least 10 percent of total body
             surface area at the time of informed consent and at registration

          -  Participants with a PASI score of greater than or equal to 12 at the time of informed
             consent and at registration

          -  Female participants of childbearing potential or males, whose partner can be pregnant,
             must agree that he/she will continuously take an appropriate contraceptive measure for
             1 year from the day of informed consent to termination of the final investigational
             treatment; in the case of childbearing potential females, pregnancy test at screening
             must be negative

          -  Participants must agree not to receive Bacillus Calmette-Guérin (BCG) vaccination and
             live vaccine inoculation for 1 year after final treatment with the investigational
             product

        Exclusion Criteria:

          -  Participants with guttate psoriasis, erythrodermic psoriasis, or pustular psoriasis

          -  Participants with a medical history of tuberculosis infection or suspected
             tuberculosis infection

          -  Participants with present or past history of chronic or recurrent infection (e.g.,
             chronic or recurrent urinary tract infection or respiratory infection)

          -  Participants with a current serious infection (e.g., sepsis, hepatitis, pneumonia, or
             pyelonephritis) or those who experienced a serious infection within the 2 month period
             before registration and including participants who received intravenous administration
             of antibiotics or antiviral agents within the 2 month period before registration

          -  Participants with a current or past history of malignant tumors (except for basal cell
             carcinoma, intraepidermal squamous cell carcinoma in the skin and uterine cervical
             squamous cell carcinoma, whose treatment was completed and no sign suggesting a
             recurrence has been observed, and squamous cell carcinoma in the skin whose treatment
             was completed and no sign suggesting a recurrence has been observed in the past 5
             years)
Clinical trial NCT00097968 (phase 3, status: completed)
Conditions: graft rejection
ICD codes: T86.830, T86.820
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adult with an established cardiac allograft vasculopathy defined as any
             new luminal irregularity on coronary angiography.

          -  Patient must be on statins at study entry.

          -  Patient who is more than 12 months post-transplant.

        Exclusion Criteria:

          -  Patient with a serum creatinine value >2.0 mg/dL.

          -  Patient with a biopsy-proven acute rejection episode (>= ISHLT 3A) within 6 months
             prior to study entry.

          -  Patient who had received any investigational drug within 4 weeks prior to study entry.
Clinical trial NCT01103388 (phase 3, status: terminated)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    closed early due to slow patient accrual and sponsor's withdrawal of support.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with diffuse large B cell non-Hodgkin's lymphoma who are 5-6 months status
             post an autologous stem cell transplant and are in CR. Patients who are positive for
             t(14;18) by PCR or for BCL-2 by Southern blot are eligible provided there is no other
             disease present.

          2. Absolute neutrophil count (ANC) > 1500/mm3 independent of growth factor support

          3. No evidence of symptomatic cardiac or pulmonary disease

          4. Platelet count > 75,000 mm3

          5. Zubrod performance status of 2 or less.

          6. Negative pregnancy test in patients of "child bearing potential"

        Exclusion Criteria:

          1. Uncontrolled active infection

          2. Severe concomitant medical or psychiatric illness

          3. Serum bilirubin > 2.0 mg/dl 4) Transaminases > 2xULN 5) Serum creatinine > 2.0 mg/dl
Clinical trial NCT00144456 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: ed-71, alfacalcidol, ed-71 placebo, alfacalcidol placebo
SMILES: [H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Eligibility criteria:

        Inclusion Criteria:

          -  Osteoporotic patients who meet any of the following condition:

               1. with at least one fragility fracture,

               2. above 70 year-old with bone mineral density below 70% young adult mean,

               3. with bone mineral density below 60% young adult mean

          -  Women three years or more after menopause or men

        Exclusion Criteria:

          -  Current disorders such as primary hyperparathyroidism, Cushing's syndrome,gonadal
             insufficiency, poorly controlled diabetes mellitus or other causes of secondary
             osteoporosis

          -  A history or suspicion of active urolithiasis at any time

          -  Use of bisphosphonates in the past 12 months

          -  Use of medications known to affect bone in the past 2 months

          -  Abnormal serum calcium, urinary calcium, serum creatinine or liver function tests